Generic Makers Fear Weakening Of Hatch-Waxman Rules

Law360, New York (July 27, 2005, 12:00 AM EDT) -- U.S. generic drug makers are wary of plans to reform the U.S. patent system, fearing that the powerful brand-name drug lobby will use the process to water down landmark legislation that paved the way for the generic pharmaceuticals industry.

The industry fears that some provisions in the bill – especially a change in the standards for inequitable conduct during the patent application process – could fundamentally alter the rules of the game to give the upper hand to drug originators in patent litigation.

“What might appear...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.